Sign up to save your podcasts
Or
Share Immunotherapy series | Selecting between first-line therapies in stage IV NSCLC
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Immunotherapy series | Selecting between first-line therapies in stage IV NSCLC
Several immune checkpoint inhibitors have indications in non small-cell lung cancer (NSCLC), but it is not always easy to decide which patients to treat when, and with which regimen. In today’s episode, we’ve invited Professor Martin Reck from the Lung Clinic Grosshansdorf in Germany to answer some of our questions about best practice when considering immune checkpoint inhibitors for patients with NSCLC.
References:
Postmus PE, et al. Annals of Oncology. 2017; 28: iv1-iv21
Socinski MA et al. JCO. 2019; 37(15_suppl): 9012-9012
Pacheco JM. Translational Lung Cancer Research. 2019; 8(5): 723-727
Funazo T et al. J Thorac Oncol. 2017; 12(9): e140-e141
Sridhar S et al. Clin Lung Cancer. 2019; 20(6): e601-e608
Chai Q-Q et al. Frontiers in Pharmacology. 2019; 10:1260
Peng M et al. OncoTargets and Therapy. 2018; 11: 7369-7383
Gadgeel S et al. JCO. 2020; 38(14): 1505-1517
Ettinger DS et al. J Natl Compr Canc Netw. 2017; 15(4): 504-535
Access more free education today! Visit the website, follow us on Twitter (@onckip) or connect on LinkedIn.
This independent educational activity is supported by an educational grant from Merck, Sharpe & Dohme Corp. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; MSD corp. has had no influence on the content of this education.
View all episodes
By Liberum IMESeveral immune checkpoint inhibitors have indications in non small-cell lung cancer (NSCLC), but it is not always easy to decide which patients to treat when, and with which regimen. In today’s episode, we’ve invited Professor Martin Reck from the Lung Clinic Grosshansdorf in Germany to answer some of our questions about best practice when considering immune checkpoint inhibitors for patients with NSCLC.
References:
Postmus PE, et al. Annals of Oncology. 2017; 28: iv1-iv21
Socinski MA et al. JCO. 2019; 37(15_suppl): 9012-9012
Pacheco JM. Translational Lung Cancer Research. 2019; 8(5): 723-727
Funazo T et al. J Thorac Oncol. 2017; 12(9): e140-e141
Sridhar S et al. Clin Lung Cancer. 2019; 20(6): e601-e608
Chai Q-Q et al. Frontiers in Pharmacology. 2019; 10:1260
Peng M et al. OncoTargets and Therapy. 2018; 11: 7369-7383
Gadgeel S et al. JCO. 2020; 38(14): 1505-1517
Ettinger DS et al. J Natl Compr Canc Netw. 2017; 15(4): 504-535
Access more free education today! Visit the website, follow us on Twitter (@onckip) or connect on LinkedIn.
This independent educational activity is supported by an educational grant from Merck, Sharpe & Dohme Corp. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; MSD corp. has had no influence on the content of this education.